1. Aubele, M., Schmitt, M., Napieralski, R., Paepke, S., Ettl, J., Absmaier, M., . . . Kiechle, M. (2017). The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Dis Markers, 2017, 4934608. doi:10.1155/2017/4934608

  2. Uhl, B., Gevensleben, H., Tolkach, Y., Sailer, V., Majores, M., Jung, M., . . . Kristiansen, G. (2017). PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. J Mol Diagn, 19(1), 107-114. doi:10.1016/j.jmoldx.2016.08.008

  3. Luan, Z. M., Zhang, H., & Qu, X. L. (2016). Prediction efficiency of PITX2 DNA methylation for prostate cancer survival. Genet Mol Res, 15(2). doi:10.4238/gmr.15026750

  4. Sailer, V., Holmes, E. E., Gevensleben, H., Goltz, D., Droge, F., de Vos, L., . . . Dietrich, D. (2016). PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. Oncotarget, 7(46), 75827-75838. doi:10.18632/oncotarget.12417

  5. Uhl, B., Dietrich, D., Branchi, V., Semaan, A., Schaefer, P., Gevensleben, H., . . . Matthaei, H. (2016). DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS One, 11(10), e0165769. doi:10.1371/journal.pone.0165769

  6. Wang, Q., Li, J., Wu, W., Shen, R., Jiang, H., Qian, Y., . . . Wang, L. (2016). Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer. Oncotarget, 7(10), 11208-11222. doi:10.18632/oncotarget.7158

  7. Litovkin, K., Joniau, S., Lerut, E., Laenen, A., Gevaert, O., Spahn, M., . . . Bollen, M. (2014). Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol, 140(11), 1849-1861. doi:10.1007/s00432-014-1738-8

  8. Vasiljevic, N., Ahmad, A. S., Carter, P. D., Fisher, G., Berney, D. M., Foster, C. S., . . . Lorincz, A. T. (2014). DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomark Med, 8(9), 1143-1150. doi:10.2217/bmm.14.41

  9. Dietrich, D., Hasinger, O., Banez, L. L., Sun, L., van Leenders, G. J., Wheeler, T. M., . . . Kristiansen, G. (2013). Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn, 15(2), 270-279. doi:10.1016/j.jmoldx.2012.11.002

  10. Dietrich, D., Hasinger, O., Liebenberg, V., Field, J. K., Kristiansen, G., & Soltermann, A. (2012). DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol, 21(2), 93-104. doi:10.1097/PDM.0b013e318240503b

  11. Banez, L. L., Sun, L., van Leenders, G. J., Wheeler, T. M., Bangma, C. H., Freedland, S. J., . . . Castanos-Velez, E. (2010). Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol, 184(1), 149-156. doi:10.1016/j.juro.2010.03.012

  12. Napieralski, R., Brunner, N., Mengele, K., & Schmitt, M. (2010). Emerging biomarkers in breast cancer care. Biomark Med, 4(4), 505-522. doi:10.2217/bmm.10.73

  13. Duffy, M. J., Napieralski, R., Martens, J. W., Span, P. N., Spyratos, F., Sweep, F. C., . . . Group, E. P. (2009). Methylated genes as new cancer biomarkers. Eur J Cancer, 45(3), 335-346. doi:10.1016/j.ejca.2008.12.008

  14. Hartmann, O., Spyratos, F., Harbeck, N., Dietrich, D., Fassbender, A., Schmitt, M., . . . Martens, J. W. (2009). DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res, 15(1), 315-323. doi:10.1158/1078-0432.CCR-08-0166

  15. Martens, J. W., Margossian, A. L., Schmitt, M., Foekens, J., & Harbeck, N. (2009). DNA methylation as a biomarker in breast cancer. Future Oncol, 5(8), 1245-1256. doi:10.2217/fon.09.89

  16. Weiss, G., Cottrell, S., Distler, J., Schatz, P., Kristiansen, G., Ittmann, M., . . . Wheeler, T. (2009). DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol, 181(4), 1678-1685. doi:10.1016/j.juro.2008.11.120

  17. Harbeck, N., Nimmrich, I., Hartmann, A., Ross, J. S., Cufer, T., Grutzmann, R., . . . Lesche, R. (2008). Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol, 26(31), 5036-5042. doi:10.1200/JCO.2007.14.1697

  18. Nimmrich, I., Sieuwerts, A. M., Meijer-van Gelder, M. E., Schwope, I., Bolt-de Vries, J., Harbeck, N., . . . Martens, J. W. (2008). DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat, 111(3), 429-437. doi:10.1007/s10549-007-9800-8

  19. Maier, S., Nimmrich, I., Koenig, T., Eppenberger-Castori, S., Bohlmann, I., Paradiso, A., . . . Treatment of Cancer PathoBiology, g. (2007). DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients–Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer, 43(11), 1679-1686. doi:10.1016/j.ejca.2007.04.025

  20. Martens, J. W., Nimmrich, I., Koenig, T., Look, M. P., Harbeck, N., Model, F., . . . Foekens, J. A. (2005). Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res, 65(10), 4101-4117. doi:10.1158/0008-5472.CAN-05-0064


Therawis Pharma GmbH

Therawis Diagnostics GmbH

Grillparzerstrasse 14

81675 Munich Germany

Tel.: +49 (0) 89 41 42 45 57 0

Fax. +49 (0) 89 41 42 45 57 40

E-Mail: info@therawis.com

Find us

Meet us

© 2018 Therawis - All Rights Reserved